Each phase of mRNA-based therapeutic development consists of specific goals, steps, and endpoints. Learn the fundamentals of manufacturing mRNA-lipid nanoparticle (LNP) drug products from discovery through to commercialization.
Establishing robust manufacturing processes will be a critical factor in expanding RNA-LNP therapeutics beyond prophylactic vaccines and toward breakthrough treatments for cancer and rare diseases. Understand key process considerations that are unique to this new class of drugs.
Alterations in the chemical structure and ratio of the LNP components affect RNA-LNP delivery, potency and biodistribution. Learn about the considerations and challenges of using ionizable lipids, including the five types of lipids used for RNA delivery.
Scale-up and downstream processing operations can greatly impact the functionality and stability of RNA-LNPs. Learn how downstream considerations can make the difference between success and failure on the path toward the commercialization of mRNA vaccines.
Advances in genome sequencing and bioinformatics have led to a wealth of information to treat disease and make disease targets druggable. Gain insight into the technologies and solutions to the delivery and economic challenges in developing genomic medicines and realizing their full potential.
This website uses cookies to ensure you get the best experience on our website. Learn more
